Skip directly to site content Skip directly to search


Español  Other Languages


Centers for Disease Control and Prevention. CDC twenty four seven. Saving Lives, Protecting People
 Search

		Submit


Tuberculosis (TB)








Supplemental Information for Video Directly Observed Therapy (vDOT) Recommendations										Related Pages
										On This Page
			Benefits of vDOTUtilizing vDOT for TB Case ManagementPreparing a Patient to Use vDOTvDOT Logistics for TB Programs
		
**Key Points**
Video directly observed therapy (vDOT) can help people with TB complete treatment.
vDOT is a type of electronic DOT (eDOT) that uses a video-enabled device (e.g., smart phone, tablet, computer) to facilitate treatment observation.
Evidence presented in Recommendations for Use of Video Directly Observed Therapy During Tuberculosis Treatment — United States, 2023 demonstrates that vDOT is associated with a higher proportion of TB medication doses being observed, and similar proportions of cases with treatment completion and microbiologic resolution, when compared with traditional in-person DOT. **Based on this evidence, CDC has updated the recommendation for DOT during TB treatment to include vDOT as an equivalent alternative to in-person DOT.**
This webpage provides considerations, concerns, and limitations as supplemental to content published in Recommendations for Use of Video Directly Observed Therapy During Tuberculosis Treatment — United States, 2023*.*Benefits of vDOT**vDOT can decrease expenses and save time.**
TB programs and patients can save money and time with the use of vDOT. Cost savings may include decreased time health care workers spend traveling for community-based DOT and decreased vehicle maintenance and fuel costs. CDC developed a vDOT Costing Tool that can be requested by TB programs to estimate or compare vDOT and traditional in-person DOT costs.
Patients who would otherwise go to a clinic for DOT may experience cost savings with vDOT related to decreased travel, clinic wait times, need for dependent care, and less time off from work.**vDOT can support treatment adherence and greater patient satisfaction with care.**
Video DOT that uses either live (synchronous) or recorded (asynchronous) videos can provide patients greater flexibility and autonomy as they undergo treatment.
Recorded vDOT can facilitate medication monitoring outside of normal clinic hours, such as on nights, weekends, and holidays. Depending on the software application being used, patients can record their medication ingestion and forward the videos to the TB program when they have internet or Wi-Fi access.
Live vDOT can facilitate medication monitoring when patients travel.This flexibility and autonomy may improve patient satisfaction.**vDOT can help TB programs conduct quality assurance activities.**
Supervisory staff can participate in monitoring during live video sessions as part of quality assurance activities. Recorded video sessions can also be viewed again as needed to verify medication ingestion.Utilizing vDOT for TB Case ManagementSupplemental Information for Video DOT Recommendations
TB programs can implement vDOT as a component of case management in most settings where traditional in-person DOT is used, including for:
Patients with HIV
Pediatric and adolescent patients, with parental or guardian support
Patients in rural areas
Patients in institutional locations, if the institutional setting regulations support patient privacy and permit the use of electronic devicesTB programs need to maintain in-person DOT capability and availability to monitor TB treatment. In-person DOT is likely the best option for:
Patients who are prescribed injectable medications
Patients who are medically fragile and need close clinical monitoring
Patients who are non-adherent to treatment with vDOT
Patients who prefer in-person DOTvDOT is not advised if a TB patient, or their daily caregiver, is unable to demonstrate comfort with or proficiency in using the vDOT platform or is unable to communicate effectively. Caution and clinical judgment are advised for patients with prior side effects to TB drugs, drug resistance, or for whom treatment failure or poor adherence (e.g., persons with memory impairment, psychiatric illness, history of non-adherence) is a concern. State TB Control Offices and TB Centers of Excellence for Training, Education, and Medical Consultation can provide additional assistance and support in treating people with TB disease.**Clinical judgment should be used to individualize DOT to each patient’s clinical status and social, emotional, mental health, environmental, and financial circumstances.**Preparing a Patient to Use vDOTPreparing a Patient to Use vDOT
vDOT can begin at the start of outpatient treatment or shortly after outpatient treatment has been initiated.
When preparing a TB patient to use vDOT, TB program staff should assess if the TB patient or the patient’s caregiver has:
Knowledge of the prescribed medication regimen and potential side effects
Awareness of how to respond to and report side effects
Capacity to take (or administer) medications
Regular access to a video-enabled phone, tablet, or computer for vDOT
Regular access to the internet or Wi-Fi
Plans to change their phone or internet service provider while on vDOT
A device and current data plan that can accommodate the TB program’s selected vDOT app
Concerns about paying monthly phone or internet costs related to vDOTAt the start of vDOT, TB programs should provide the patient with training on how to download and use the vDOT technology. Patient education and practice sessions can help patients learn vDOT protocols before sessions begin. During patient education, the teach-back method can be used to confirm if patients understand vDOT. If vDOT is initiated after in-person DOT has begun, TB programs may consider offering training on vDOT during in-person DOT sessions.
During educational sessions, it is important to discuss with the patient the circumstances that would lead to the discontinuation of vDOT and switching to in-person DOT.
Additionally, potential out-of-pocket costs related to the patient’s data plan on their personal phone and usage fees should be discussed, as appropriate.
While the patient is receiving TB treatment, incentives and enablers can be used to support adherence to therapy. Incentives are inexpensive rewards given to patients to encourage them to take their medications or to keep DOT or clinic appointments. Enablers are things that help the patient receive treatment (e.g., cash assistance, reimbursement for cellphone data plans, reimbursement for internet services). Incentives and enablers should be chosen according to each patient’s needs and are frequently offered along with DOT.vDOT Logistics for TB ProgramsImplementing an Electronic Directly Observed Therapy (eDOT) Program: A Toolkit for Tuberculosis (TB) Programs can assist TB programs in developing and implementing a TB eDOT program. To implement vDOT, TB programs will need to obtain vDOT software. TB programs should develop their own policies and protocols on the use of vDOT.
***Establishing vDOT Software***
TB programs will need to research available vDOT software compatible with their agency’s security needs, as well as allow for the level of privacy needed to secure patient information. Thus, TB programs should work with their IT departments to identify technologies that can be used on health department equipment, and are compliant with the Health Insurance Portability and Accountability Act (HIPAA).
TB programs should also consider their program needs and budget when selecting vDOT software. A few additional key features to consider are the:
languages that the software can accommodate
ability for the software to store and forward videos (i.e., perform asynchronous vDOT) if patients are in areas where internet access is weak or intermittent
compatibility of the software to work with different types of devices and operating systems***Training TB Program Staff***
TB programs should develop their own policies and protocols on the use of vDOT, including training requirements for their TB program staff. Training might be needed on:
vDOT software operations from the perspective of the program and patients
Troubleshooting the software application
Troubleshooting common audio and video problems on devices
Assessing a device’s compatibility with a software application
Protocols for vDOT sessions
Patient education on TB and vDOT
Protecting patient confidentiality
Working with interpreters
Case management and vDOT
Local laws and regulations relevant to vDOT
Selecting the appropriate DOT method for patients
Reverting to in-person DOT
TB medication administration to patients who may require assistance (e.g., infants and small children)***Addressing Potential Difficulties***
TB programs implementing vDOT might experience technical challenges while using vDOT software (e.g., software-specific malfunctions, internet connection issues, patient’s audio or video not working, poor quality recordings, inadequate memory on the device). TB program staff should receive training on how to use the vDOT software before implementing vDOT. TB program staff should also engage their local IT staff and the developers of the vDOT software to proactively address any potential issues.
Patients might also experience difficulties using the vDOT technology (e.g., unable to remember how to use the app, no phone service, low battery). Patient education, educational materials (e.g., brochures with instructions and pictures), and practice vDOT sessions at the start of and during vDOT can help lessen potential difficulties.
As with in-person DOT, TB programs implementing vDOT will need to establish procedures to confirm that the TB patient ingests the prescribed medicine. Some patients might hide pills in their mouth and spit them out later, hide medicine in clothing, or vomit the pills. If a TB patient does not adhere to treatment, treatment difficulties can arise (e.g., sputum smear reversions, delayed culture conversions, development of drug-resistant TB).
It might be difficult for the health care worker to ensure that a patient has ingested their medicine completely, especially during recorded vDOT sessions. Signs that a patient might not have ingested their medication completely include videos stopping immediately after pills are placed in a patient’s mouth, a patient spending time out of camera view or being only partially visible on screen, or a patient covering their mouth while ingesting medications. Potential solutions include watching the patient continuously from the time each pill is given to the time he or she swallows it and asking the patient to show inside their mouth while moving their tongue from side-to-side.
TB programs will also need to ensure that the TB patient can report any concerns or symptoms of side effects that they may have. Examples of side effects include fever, rash, vomiting, nausea, upset stomach, changes in eyesight or hearing, yellow skin or eyes, aching joints.
Patients using vDOT should be taught which medication side effects should be reported immediately, and how to contact health care workers without delay.
During live video sessions, staff should inquire about any potential side effects.
Patients using recorded vDOT should be instructed to report any concerns or symptoms to their health care worker at the start of each recorded vDOT session. If a patient using recorded vDOT does not acknowledge whether they have any health concerns or symptoms, TB program staff should call the patient and ask about any possible problems.If any symptoms of serious side effects are reported, a new drug supply should not be given; the patient should stop taking medication immediately. The health care worker should arrange for the patient to see their TB clinician as soon as possible.
***Reporting vDOT Data***
The 2020 Report of Verified Cases of Tuberculosis (RVCT) collects data on the administration of TB medications for all TB patients. vDOT is reported under electronic DOT (eDOT). This is because vDOT is a type of eDOT that uses a video-enabled device (e.g., smart phone, tablet, computer) to facilitate observation of medicine ingestion through a remote interaction between patients and health care workers.
Additional types of eDOT might include other electronic methods to document adherence to a medication regimen (e.g., pill bottles with medication event monitoring systems [MEMS], text message reminders, sensor-embedded pills). CDC did not review or make a recommendation for electronic methods other than vDOT, because video was considered critical to observing medication ingestion.
Jurisdictions that intend to implement vDOT should review their data collection systems to ensure compatibility to report eDOT data.
***Determining Reimbursement for vDOT***
Medicaid coverage and reimbursement varies from state to state. For more information, see the National Policy Center – Center for Connected Health Policy list of current state laws and reimbursement policies.
For information on reimbursement from private insurance companies, TB programs should check with the individual insurance company to determine if they offer reimbursement for vDOT.
							
					
							Last Reviewed:  March 22, 2023						Source: 	Division of Tuberculosis Elimination, National Center for HIV, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention
					Facebook
        Twitter
        LinkedIn
        Syndicate homeTuberculosisBasic TB Factsplus iconHow TB SpreadsLatent TB Infection and TB DiseaseSigns & SymptomsTB Risk FactorsExposure to TBTB PreventionVaccinesTB & HIV CoinfectionTB and DiabetesTB TermsPersonal StoriesTesting & Diagnosisplus iconWho Should be TestedTesting for TB InfectionTesting in BCG-Vaccinated PersonsTB Screening and Testing of Health Care PersonnelTesting During PregnancyDiagnosing latent TB infection and TB diseaseTreatmentplus iconDeciding When to Treat Latent TB InfectionTreatment Regimens for Latent TB Infection (LTBI)Treatment for TB DiseaseAdverse EventsTB Treatment of Persons Living with HIVTB Treatment and PregnancyTB Treatment for ChildrenFrequently Asked QuestionsDrug-Resistant TBResearchplus iconTB Epidemiologic Studies Consortiumplus iconResearch ProjectsPublicationsTB Trials Consortiumplus iconStudy DescriptionsBackgroundBehavioral & Social Science ResearchHealth Care Settingsplus iconTB Infection Control in Health Care SettingsResources for TB Screening and Testing of Health Care Personnelplus iconFrequently Asked QuestionsTB in Specific Populationsplus iconHealth DisparitiesAsian PersonsBlack or African American PersonsHispanic or Latino PersonsChildrenPregnancyCorrectional FacilitiesPeople Experiencing HomelessnessInternational TravelersLaboratory Informationplus iconDrug Susceptibility TestingFalse-Positive Investigation ToolkitInterim Laboratory Biosafety Guidance for XDR  tuberculosis strainsModel Performance Evaluation Program (MPEP)Rapid Molecular Testing to Detect Drug-Resistant TB in the USplus iconExecutive SummaryIntroductionBackground on Tests for Molecular Detection of DRGeneral Considerations and Principles for a Molecular DR Testing ServicePossible Scenarios and Scope of Testing for a Molecular DR Testing ServiceResearch NeedsGeneral Recommendations of the Expert PanelCommunication Plan for the ReportRecommendationsReferencesPanel Members and CDC ParticipantsAppendix 1Appendix 2Appendix 3The Uses of Nucleic Acid Amplification Tests for the Diagnosis of TBplus iconGeneral ConsiderationsGeneral Recommendations of the Expert PanelRecommendations to ACET, CDC, DTBEData & Statisticsplus iconTB Incidence in the United StatesReported TB in the US, 2022 Surveillance Reportplus iconNational DataReporting Area DataRisk FactorsDemographicsTB Treatment and Case OutcomesDrug-Resistant TBMolecular SurveillanceTuberculosis in the United States, 2022 (Slide Set)Archived Surveillance Reports and Slide Sets2021 State and City ReportArchived State and City ReportsProfessional Resources & Toolsplus iconTools for Healthcare ProvidersResources for TB Programsplus iconStrengthening Civil Surgeons’ Capacity to Improve LTBI Surveillance and Outcomes Among Status AdjustersNotice of Funding Opportunity (NOFO)Program EvaluationTB Centers of ExcellenceTB Elimination AllianceTB Genotypingplus iconConventional TB GenotypingWhole Genome SequencingTB GIMSAnalytic ToolsLatent Tuberculosis Infection ResourcesPublications & Productsplus iconPatient and Public MaterialsFact SheetsGuidelinesplus iconControl & EliminationDrug-Resistant TBInfection Control & PreventionLaboratory & GenotypingTB & HIVTB in Specific PopulationsTesting & DiagnosisTreatmentVaccines & ImmunizationsArchived TB GuidelinesGuides & Toolkitsplus iconAggregate ReportsCDC TB Surveillance TrainingCore CurriculumEffective TB Interviewing for Contact InvestigationEthnographic GuidesFalse-Positive Investigation ToolkitForging Partnerships to Eliminate TuberculosisGuide to Application of GenotypingLTBI: A Guide for Primary Health Care ProvidersMantoux Tuberculin Skin Testing ProductsReport of Verified Case of Tuberculosis (RVCT)Self-Study ModulesTB Contact Investigation Interviewing Skills CourseTB eDOT ToolkitUnderstanding the TB Cohort Review ProcessNewslettersplus iconTB Notes, No. 4, 2023TB Notes, No. 3, 2023TB Notes. No. 2, 2023TB Notes. No. 1, 2023TB Notes, No. 4, 2022TB Notes, No. 3, 2022TB Notes, No. 2, 2022TB Notes, No. 1, 2022TB Notes, No. 4, 2021TB Notes, No. 3, 2021TB Notes, No. 2, 2021TB Notes, No. 1, 2021Pamphlets, Brochures, Bookletsplus iconQuestions and AnswersPatient Education SeriesTuberculosis - Get the FactsTuberculosis - The Connection between TB and HIV12-Dose Regimen for Latent TB Infection-Patient Education BrochurePostersplus iconMantoux Tuberculin Skin Test Wall ChartWorld TB DayThink TBStop TBTake on TBReports & Articlesplus iconDTBE Authored Journal ArticlesTuberculosis Laboratory Aggregate ReportsSlide Setsplus iconIntroduction to TuberculosisEpidemiology of Tuberculosis Among Non-U.S.​–Born Persons in the United States, 1993–2016Self-Study Modules on Tuberculosis, 1-5 Slide SetsThe Tuberculosis (TB) in Correctional Settingsplus iconFacilitator GuideIntroduction to TB GenotypingEpidemiology of Tuberculosis in Correctional Facilities, United States, 1993-2017Prevention and Control of Tuberculosis in Correctional and Detention FacilitiesGuidelines for Preventing the Transmission of M. TB in Health care SettingsInvestigation of Contacts of Persons with Infectious TBEpidemiology of Pediatric Tuberculosis in the United StatesTargeted Tuberculosis Testing and Treatment of Latent Tuberculosis InfectionElectronic Tools & ResourcesWeb-Based Courses & Webinarsplus iconTB 101 for Health Care WorkersContent SyndicationInfographicsplus iconSocial Media GraphicsCustomizable Take on TB Infographic with InstructionsEventsWorld TB Dayplus iconU.S. TB ChampionsHistoryFeaturesplus iconTB Risk FactorsTreating Latent TB Infection with Short-Course RegimensWorld Tuberculosis (TB) Day 2021World Tuberculosis (TB) Day 2020Linksplus iconState TB Control OfficesAbout Usplus iconMission Statement and Activitiesplus iconDTBE Strategic PlanNational TB Program ObjectivesOrganization ChartAdvisory Groupsplus iconFederal TB Task Force To receive email updates about this page, enter your email address: Email Address			What's this?				Submit


About CDC
					Contact Us
					800-232-4636
 Facebook Twitter Instagram LinkedIn Youtube Pinterest Snapchat
 CONTACT CDC
				Contact Us
							Call 800-232-4636
							Email Us
			ABOUT CDC
				About CDC
							Jobs
							Funding
			POLICIES
				Accessibility
							External Links
							Privacy
							Policies
							No Fear Act
							FOIA
							OIG
							Nondiscrimination
							Vulnerability Disclosure Policy
			CONNECT WITH US
				Facebook
								Twitter
								Instagram
								LinkedIn
							Youtube
								Pinterest
								Snapchat
								Email
			LANGUAGES
				Español
							繁體中文
							Tiếng Việt
							한국어
							Tagalog
							Русский
							العربية
							Kreyòl Ayisyen
							Français
							Polski
							Português
							Italiano
							Deutsch
							日本語
							فارسی
							English


U.S. Department of Health & Human Services
			Accessibility
			External Links
			Privacy
			Policies
			No Fear Act
			FOIA
			Nondiscrimination
			OIG
			Vulnerability Disclosure Policy
			USA.gov


Exit Notification / Disclaimer Policy Close
 Links with this icon  indicate that you are leaving the CDC website. The Centers for Disease Control and Prevention (CDC) cannot attest to the accuracy of a non-federal website.
				Linking to a non-federal website does not constitute an endorsement by CDC or any of its employees of the sponsors or the information and products presented on the website.
				You will be subject to the destination website's privacy policy when you follow the link.
				CDC is not responsible for Section 508 compliance (accessibility) on other federal or private website. Website Disclaimers
 Cancel Continue